EVENTS · ABBV
PEERS
EARNINGS
AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases. AbbVie focuses on major therapeutic areas including immunology, oncology, neuroscience, eye care, aesthetics, and virology, serving patients with chronic autoimmune conditions, blood cancers, inflammatory disorders, and other specialized medical needs. The company’s portfolio includes branded prescription medicines and advanced therapies distributed through physicians, wholesalers, specialty pharmacies, healthcare facilities, and other healthcare channels. AbbVie also supports contract manufacturing services for selected biologics and pharmaceutical processes. Headquartered in North Chicago, Illinois, AbbVie operates as a research-driven healthcare business with a broad international footprint and a strong role in specialty medicine markets.
Drug makers rallied broadly after Amgen and Novo Nordisk both raised their full year forecasts on strong results, lifting the whole group including AbbVie
| Series | 1W | 1M |
|---|---|---|
| ABBV | +3.1% | +10.6% |
| Peers | +7.1% | +14.1% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 40 | 59 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q3 FY2026 | 3.74 | 3.82 | +2.14% | −0.70% |
| Q2 FY2026 | 3.68 | 3.65 | −0.71% | −4.78% |
| Q1 FY2026 | 2.65 | 2.65 | +0.18% | +6.89% |
| Q4 FY2025 | 2.71 | 2.71 | +0.17% | −2.94% |
| Q3 FY2025 | 1.81 | 1.86 | +2.75% | −7.12% |
| PERIOD | EPS EST | REV EST |
|---|---|---|
| Q4 FY2026 | 3.89 | 18.30B |
| FY2026 | 13.96 | 67.60B |
| FY2027 | 16.20 | 73.60B |
| Series | 1W | 1M |
|---|---|---|
| ABBV | +3.1% | +10.6% |
| Peers | +7.1% | +14.1% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 40 | 59 |
